杜氏肌营养不良患者接受高剂量rAAV9基因治疗后死亡
一名27岁杜氏肌营养不良患者接受剂量为1×10¹⁴载体基因组/千克体重的rAAV9定制CRISPR-转录激活因子治疗,转基因组设计用于上调皮质肌营养不良蛋白。治疗后出现轻度心功能障碍和心包积液,随后发生急性呼吸窘迫综合征(ARDS)和心脏骤停,转基因组治疗6天后心脏骤停,2天后死亡。尸检显示严重弥漫性肺泡损伤,肝脏转基因组表达极少,器官中无AAV9抗体或效应T细胞反应证据。
要点
- 患者接受1×10¹⁴载体基因组/千克体重的rAAV9治疗后出现轻度心功能障碍和心包积液。
- 转基因组治疗6天后发生ARDS和心脏骤停,2天后死亡。
- 尸检显示严重弥漫性肺泡损伤,提示先天免疫反应导致ARDS。
核心结论
- 这些发现表明,先天免疫反应导致接受高剂量rAAV基因治疗的晚期杜氏肌营养不良患者发生ARDS。
研究设计与样本
- 对一名27岁杜氏肌营养不良患者进行rAAV9介导的定制CRISPR-转录激活因子治疗,剂量为1×10¹⁴载体基因组/千克体重。
主要发现
- 治疗后出现轻度心功能障碍和心包积液,随后发生ARDS和心脏骤停,转基因组治疗6天后心脏骤停,2天后死亡。
- 尸检显示严重弥漫性肺泡损伤。
- 肝脏转基因组表达极少,器官中无AAV9抗体或效应T细胞反应证据。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We treated a 27-year-old patient with Duchenne's muscular dystrophy (DMD) with recombinant adeno-associated virus (rAAV) serotype 9 containing dSaCas9 (i.e., "dead" Staphylococcus aureus Cas9, in which the Cas9 nuclease activity has been inactivated) fused to VP64; this transgene was designed to up-regulate cortical dystrophin as a custom CRISPR-transactivator therapy. The dose of rAAV used was 1×1014 vector genomes per kilogram of body weight. Mild cardiac dysfunction and pericardial effusion developed, followed by acute respiratory distress syndrome (ARDS) and cardiac arrest 6 days after transgene treatment; the patient died 2 days later. A postmortem examination showed severe diffuse alveolar damage. Expression of transgene in the liver was minimal, and there was no evidence of AAV serotype 9 antibodies or effector T-cell reactivity in the organs. These findings indicate that an innate immune reaction caused ARDS in a patient with advanced DMD treated with high-dose rAAV gene therapy. (Funded by Cure Rare Disease.).
引用
- Lek A, Wong B, Keeler A, et al. Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy. N Engl J Med. 2023. PMID: 37754285. doi:10.1056/NEJMoa2307798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。